Latest Conference Articles

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.

Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.

Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.

In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.

In a shifting environment, pharmacy success is no longer just about scale but about earning patient trust through consistency and effectively managing affordability.

Community pharmacies have become one of the most accessible points of care for patients, especially in rural and underserved communities.

Pharmacists expand into vaccines and telehealth, but state laws and reimbursement gaps persist.

Medicare’s new GLP‑1 bridge program launches soon, easing access without shortages, and pharamcists are at the focal point of these transitions.

CMS pilots BALANCE and GLP-1 Bridge models to widen Medicare/Medicaid obesity drug coverage, spotlighting pharmacists’ role in access and safe therapy.

Drug pricing rules reshape pharmacy and manufacturer strategies, as transparency grows and 340B reforms intensify scrutiny.

Specialty pharmacy shifts toward holistic, empathetic care, easier oral therapies, and wider community access to advanced cell and gene treatments.

Pharmacy leaders face rapid change, which can boost agility and automate repetitive tasks.

These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.

Pharmacies can use technology and artificial intelligence to cut specialty drug complexity, boost access and adherence, and help pharmacists guide patients.

Digital specialty pharmacy, AI-driven intent, and mega-blockbuster drugs reshape patient engagement, access, and long-term adherence strategies.

Pharmacy benefit manager reforms, gene therapy scale-up, artificial trust risks, and more reshape specialty pharmacy.

Real-time prescription pricing and auto-applied discounts cut pharmacy counter surprises, speed therapy, and free pharmacists for patient-focused care.

Lower patient caps shift costs to community pharmacies, fueling pharmacy benefit manager fees, mail-order growth, and pharmacy deserts.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

Travis Wolff, PharmD, BCACP, presents on the current landscape of medical billing in pharmacy practice and the steps pharmacists can take to realize a significantly higher profit margin.

Suzanne K. Higginbotham, PharmD, BCACP, CTTS, CDCES, further discusses her APhA 2026 presentation titled “Real-Time. Real Change. Rethinking CGM for Today's Patient.”

This study indicates that stopping the medication is noninferior to continuing it indefinitely in terms of preventing death, recurrent heart attacks, or hospitalizations.